Navigation Links
Renhuang Pharmaceuticals, Inc. Retains CCG Elite

LOS ANGELES and HARBIN, China, Feb. 14 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (OTC Bulletin Board: RHGP) ("Renhuang" or "the Company"), a leading pharmaceutical company in China, today announced that it has retained CCG Elite to design and execute its investor relations campaign.

Through its GMP certified facilities, the Company manufactures over 200 types of western, traditional Chinese medicines (TCM), and branded pharmaceuticals. The Company sells raw materials and finished products using its extensive distribution network and third party distributors throughout China. Renhuang controls an estimated 70% of China's natural source of Acanthopanax (also known as Siberian Ginseng), a widely used drug for multiple indications, and hence dominates the market for Acanthopanax-based medicinal and nutraceutical products. The Company's distribution network includes over 3,000 sales agents in 70 sales centers across 24 districts, covering over 50% of the greater China. Additionally, Renhuang exports its pharmaceuticals to Russia and Southeast Asia.

Using its strong R&D team, Renhuang performs contract research and development services. Lead pharmaceuticals include: Acanthopanax based natural medicine products for treating depression, melancholy and other illnesses, Biopharmaceuticals (Shark Power Health Care and Ginseng Ointment) for multiple indications, and TCM. For nine months ending July 31, 2007, Renhuang's revenue totaled $20.1 million, and net income was $8.5 million, up 175% from the same period in the prior year.

"Renhuang is a fast growing drug manufacturer and distributor in China," said Mr. Li Shaoming, Chairman & CEO of Renhuang Pharmaceuticals, Inc. "We are very excited to work with CCG Elite to maximize our stockholders' value by improving our visibility with the investment community and with the financial media."

Pharmaceutical sales in China are expected to increase by over 13 percent annually, reaching $24 billion by 2010. Higher demand for pharmaceuticals in China is expected over the coming years due to growing affluence, size of the middle class, and the aging population. Additionally, the Company expects higher demand for its products in the foreign markets over the coming years.

Renhuang has a pipeline of pharmaceuticals including Lyophilized Syringin Powder for Injection, a novel anti-depression Chinese medicine, and plans to distribute them pending the approval from the Chinese State Food and Drug Administration (SFDA). Additional products in development include food antiseptic, immune system and diagnostics. Furthermore, the Company plans to build its brands by further expanding its market share in major cities such as Beijing and Shanghai. Other growth strategies include direct sales of pharmaceuticals to top tier hospitals, and increasing its branded product sales in the highly populated rural China. Additionally, the Company plans to grow through strategic partnership and acquisitions.

"Renhuang is a leading pharmaceutical company with solid manufacturing capabilities, branded products, extensive distribution network, strong R&D team, and an experienced management," said Crocker Coulson, President of CCG Elite. "The Company is well-positioned to take advantage of growing demand for pharmaceuticals in China. Through our integrated investor relations initiatives, we will introduce the Company to fund managers and analysts focusing on high growth equities from China."

About CCG Elite

CCG Elite is uniquely positioned to provide an outsourced, high-level investor relations solution that combines in-depth understanding of Asia's corporate culture and economic scene with a direct pipeline into the leading funds and broker-dealers in the United States. CCG Elite is a global, full-service investor relations agency with corporate headquarters in Los Angeles, and offices in New York, Newport Beach, Dallas, Hong Kong, Beijing and Shanghai. For further information, contact CCG Elite or visit the Company's website at .

About Renhuang Pharmaceuticals, Inc.

Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western, traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company's GMP-certified manufacturing facilities, containing cutting-edge technologies and advance equipment, are capable of producing a many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceuticals using its broad distribution channels and third party distributors throughout China. The Company's distribution network includes over 2,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit .

Safe Harbor Statement

This press release contains certain statements that may include 'forward-looking statements' as defined in the Securities Act of 1933, and the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein are 'forward-looking statements'. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with and available from the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Renhuang Pharmaceuticals, Inc.

Ms. Gina Gao, IR Contact

Tel: +86-451-5762-0378


CCG Elite Investor Relations Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)


SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
2. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
3. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
4. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
5. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
6. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
7. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
8. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
9. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
10. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare ... IT Healthcare was recognized as a finalist in the category of Digital Solutions ...
(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 /PRNewswire/ -- Royal Philips  ... an X-ray imaging software that produces high-contrast images for ... use a grid, at the 2015 Radiological Society ... SkyFlow is Philips, first digital imaging solution providing grid-like ... improves clinician,s workflow and supports "first-time-right imaging" by decreasing ...
(Date:12/1/2015)... 1, 2015 A federal court has denied the ... a lawsuit filed by the Pharmaceutical Care Management Association (PCMA) ... a new law that forces employers and consumers to pay ... Arkansas must now defend a law that raises ... and CEO Mark Merritt . --> ...
(Date:12/1/2015)... 2015 --> --> ... Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, ... Pipeline Analysis - Global Forecast to 2020", published by MarketsandMarkets, ... 73,529.2 Million by 2020 from USD 40,281.6 Million in 2015, ... Browse 37 market data T ...
Breaking Medicine Technology: